Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients

This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.
Head/Neck
Phase III
Adults
Not Available
Not Available
Choe, Jennifer
International
Vanderbilt University
02-21-2025
Treatment
VICC-DTHAN23576
NCT06496178

Eligibility

18 Years and older
ALL
false
Inclusion Criteria:

Signed ICF before initiation of any study procedures.

Signed ICF before initiation of any study procedures.

Age 18 years at signing of ICF.

Age 18 years at signing of ICF.

Histologically previously confirmed HNSCC with evidence of metastatic or locally advanced disease not amenable to standard therapy with curative intent.

Histologically previously confirmed HNSCC with evidence of metastatic or locally advanced disease not amenable to standard therapy with curative intent.

HNSCC patients progressed on or after anti-PD-1 therapy and platinum-containing therapy.

HNSCC patients progressed on or after anti-PD-1 therapy and platinum-containing therapy.

The eligible HNSCC primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx.

The eligible HNSCC primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx.

Documentation of p16 status (positive or negative) by local laboratory IHC for patients with primary oropharyngeal cancer.

Documentation of p16 status (positive or negative) by local laboratory IHC for patients with primary oropharyngeal cancer.

A baseline new tumor sample unless the patient has an available tumor sample as an FFPE block with sufficient material.

A baseline new tumor sample unless the patient has an available tumor sample as an FFPE block with sufficient material.

Measurable disease as defined by RECIST v1.1 by radiologic methods.

Measurable disease as defined by RECIST v1.1 by radiologic methods.

ECOG PS of 0 or 1

ECOG PS of 0 or 1

Life expectancy 12 weeks, as per investigator

Life expectancy 12 weeks, as per investigator

Adequate organ function (as per protocol)

Adequate organ function (as per protocol)



Exclusion Criteria:

Central nervous system metastases that are untreated or symptomatic, or require radiation, surgery, or continued steroid therapy to control symptoms within 14 days of study entry.

Central nervous system metastases that are untreated or symptomatic, or require radiation, surgery, or continued steroid therapy to control symptoms within 14 days of study entry.

Known leptomeningeal involvement

Known leptomeningeal involvement

Any systemic anticancer therapy within 4 weeks of the first dose of study treatment.

Any systemic anticancer therapy within 4 weeks of the first dose of study treatment.

Major surgery or radiotherapy within 3 weeks of the first dose of study treatment.

Major surgery or radiotherapy within 3 weeks of the first dose of study treatment.

Persistent Grade >1 clinically significant toxicities related to prior antineoplastic therapies

Persistent Grade >1 clinically significant toxicities related to prior antineoplastic therapies

History of hypersensitivity reaction to any of the excipients of treatment required for this study.

History of hypersensitivity reaction to any of the excipients of treatment required for this study.

Unstable angina; history of congestive heart failure of Class II-IV New York Heart Association (NYHA) criteria, or serious cardiac arrhythmia requiring treatment or history of myocardial infarction within 6 months of study entry

Unstable angina; history of congestive heart failure of Class II-IV New York Heart Association (NYHA) criteria, or serious cardiac arrhythmia requiring treatment or history of myocardial infarction within 6 months of study entry

History of prior malignancies with the exception of excised cervical intraepithelial neoplasia or nonmelanoma skin cancer, or curatively treated cancer deemed at low risk for recurrence with no evidence of disease

History of prior malignancies with the exception of excised cervical intraepithelial neoplasia or nonmelanoma skin cancer, or curatively treated cancer deemed at low risk for recurrence with no evidence of disease

Current dyspnea at rest of any origin, or other diseases requiring continuous oxygen therapy

Current dyspnea at rest of any origin, or other diseases requiring continuous oxygen therapy

Current serious illness or medical conditions including, but not limited to, uncontrolled active infection, clinically significant pulmonary, metabolic or psychiatric disorders

Current serious illness or medical conditions including, but not limited to, uncontrolled active infection, clinically significant pulmonary, metabolic or psychiatric disorders

Patients with known infectious diseases (as per protocol)

Patients with known infectious diseases (as per protocol)

Pregnant or breastfeeding patients

Pregnant or breastfeeding patients

Patient has a primary tumor site of nasopharynx (any histology).

Patient has a primary tumor site of nasopharynx (any histology).

To learn more about any of our clinical
trials, call 615-936-8422.